AbbVie (ABBV) EBIT Growth (3y) (2015 - 2026)
Powered by 
Analysis
AbbVie (ABBV) EBIT Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 7.73% |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -15.60% |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 53.28% |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 1.82% |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 27.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.54% |
| Mar 31, 2026 | 12.96% |
| Dec 31, 2025 | -6.18% |
| Sep 30, 2025 | -25.49% |
| Jun 30, 2025 | 14.10% |
| Mar 31, 2025 | -7.50% |
| Dec 31, 2024 | -31.88% |
| Sep 30, 2024 | -3.82% |
| Jun 30, 2024 | -3.44% |
| Mar 31, 2024 | -11.98% |
| Dec 31, 2023 | -5.22% |
| Sep 30, 2023 | -11.18% |
| Jun 30, 2023 | 81.73% |
| Mar 31, 2023 | -8.41% |
| Dec 31, 2022 | 11.62% |
| Sep 30, 2022 | 20.71% |
| Jun 30, 2022 | -1.04% |
| Mar 31, 2022 | 16.15% |
| Dec 31, 2021 | 59.77% |
| Sep 30, 2021 | 10.88% |